Abstract
Screening extracts and drug entities for antidiabetic bioactivity is essentially limited to animal models as the processes leading to hyperglycemia and the complications of diabetes involve more than one organ. Further, in vitro results seldom translate into meaningful in vivo outcomes especially in a disease such as Diabetes Mellitus. In vivo studies on specialized animal models have allowed great progress in tailoring research questions towards individualized genetic and biochemical contributors and their effect on the pathogenesis of the disease processes. Various disease models have been used either through genetic-manipulation (transgenic models) or through chemical induction (disease-induced models). Although there is a surplus of animal models (spontaneous and induced) to study Type I and Type II diabetes, there is no ideal or standard model for studying the individualized effects of various classes of antidiabetic drugs. Rodents, most commonly rats and mice, have been used by researchers as animal models of the disease and both normoglycemic and diabetic animals are used to assess the antidiabetic activities of drugs or extracts under investigation. Screening for antidiabetic activities can be achieved by measuring a wide range of biomarkers and end points including blood glucose and insulin levels.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
King H (1999) WHO and the International Diabetes Federation: regional partners. Bull World Health Organ 77:954
Wilcox G (2005) Insulin and insulin resistance. Clin Biochem Rev 26(2):19–39
Butler AE, Jang J, Gurlo T, Carty MD, Soeller WC, Butler PC (2004) Diabetes due to a progressive defect in beta-cell mass in rats transgenic for human islet amyloid polypeptide (HIP rat): a new model for type 2 diabetes. Diabetes 53:1509–1516
Matveyenko AV, Butler PC (2006) Beta-cell deficit due to increased apoptosis in the human islet amyloid polypeptide transgenic (HIP) rat recapitulates the metabolic defects present in type 2 diabetes. Diabetes 55:2106–2114
Goldsbury C, Goldie K, Pellaud J, Seelig J, Frey P, Muller SA, Kistler J, Cooper GJ, Aebi U (2000) Amyloid fibril formation from full-length and fragments of amylin. J Struct Biol 130:352–362
Garvey WT, Maianu L, Hancock JA, Golichowski AM, Baron A (1992) Gene expression of GLUT4 in skeletal muscle from insulin-resistant patients with obesity, IGT, GDM, and NIDDM. Diabetes 41:465–475
Pedersen O, Bak JF, Andersen PH, Lund S, Moller DE, Flier JS, Kahn BB (1990) Evidence against altered expression of GLUT1 or GLUT4 in skeletal muscle of patients with obesity or NIDDM. Diabetes 39:865–870
Brozinick JT Jr, McCoid SC, Reynolds TH, Nardone NA, Hargrove DM, Stevenson RW, Cushman SW, Gibbs EM (2001) GLUT4 overexpression in db/db mice dose-dependently ameliorates diabetes but is not a lifelong cure. Diabetes 50:593–600
Gibbs EM, Stock JL, McCoid SC, Stukenbrok HA, Pessin JE, Stevenson RW, Milici AJ, McNeish JD (1995) Glycemic improvement in diabetic db/db mice by overexpression of the human insulin-regulatable glucose transporter (GLUT4). J Clin Invest 95:1512–1518
Wu KK, Huan Y (2008). Streptozotocin-induced diabetic models in mice and rats. Curr Protoc Pharmacol Chapter 5, Unit 5:47
Satyanarayana S, Sekhar JR, Kumar KE, Shannika LB, Rajanna B, Rajanna S (2006) Influence of selenium (antioxidant) on gliclazide induced hypoglycaemia/anti hyperglycaemia in normal/alloxan-induced diabetic rats. Mol Cell Biochem 283:123–127
Schaffer L, Brissette RE, Spetzler JC, Pillutla RC, Ostergaard S, Lennick M, Brandt J, Fletcher PW, Danielsen GM, Hsiao KC, Andersen AS, Dedova O, Ribel U, Hoeg-Jensen T, Hansen PH, Blume AJ, Markussen J, Goldstein NI (2003) Assembly of high-affinity insulin receptor agonists and antagonists from peptide building blocks. Proc Natl Acad Sci USA 100:4435–4439
Caccetta R, Ireng A, Helmerhorst E, Parsons R (2013) Teucrium polium significantly lowers blood glucose levels acutely in normoglycaemic male Wistar rats; a comparative to insulin. Submitted for publication
Grundy SM (1999) Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol 83:25F–29F
Jung M, Park M, Lee HC, Kang YH, Kang ES, Kim SK (2006) Antidiabetic agents from medicinal plants. Curr Med Chem 13:1203–1218
Baribault H (2010) Mouse models of type II diabetes mellitus in drug discovery. Methods Mol Biol 602:135–155
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Caccetta, R., Al Salami, H. (2013). Screening for Antidiabetic Activities. In: Roessner, U., Dias, D. (eds) Metabolomics Tools for Natural Product Discovery. Methods in Molecular Biology, vol 1055. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-577-4_15
Download citation
DOI: https://doi.org/10.1007/978-1-62703-577-4_15
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-576-7
Online ISBN: 978-1-62703-577-4
eBook Packages: Springer Protocols